Paul Matteis
Managing Director & Head of Therapeutics Research Stifel
Paul Matteis joined Stifel in 2018. Based out of the firm’s Boston office, he serves as a Managing Director and Head of Biotech Research.
Previously, Paul was a Senior Biotechnology Analyst covering small-cap and mid-cap companies at Leerink, with a focus on neuroscience, central nervous system and rare disease. Before this, he was a Research Assistant at the Harvard Division of Sleep Medicine at Brigham & Women’s Hospital.
Paul was named a “Runner Up” in Small/Mid Cap Biotechnology in 2019-2024, as well as a “Rising Star” by Institutional Investor in both 2015 and 2016, as part of the publication’s All-America Research Team rankings. He attended Skidmore College in New York, where he studied Psychology and Pre-Medical Sciences and graduated Phi Beta Kappa
Seminars
- How emerging scientific modalities such as circuit level biomarkers, data integrated platforms, and next generation neuroplastogens are shaping the future landscape of neuropsychiatric innovation
- What investors and R&D leaders look for in early stage assets, including differentiated mechanisms, strong biomarker strategies, and clear pathways to clinical and commercial de risking
- How strategic capital allocation across discovery, translational technologies, and Phase 2/3 ready programs can build sustainable, multi mechanism therapeutic pipelines
- Where the field is heading next, and how cross disciplinary innovation and coordinated investment can accelerate the next transformative wave in neuropsychiatric therapeutics
